<?xml version="1.0"?>
  <rss version="2.0">
    <channel>
      <title>Perindopril News : GoldBamboo.com</title>
      <link>http://goldbamboo.com/</link>
      <description>Perindopril News from GoldBamboo.com</description>
      <language>en-us</language>
      <copyright>&amp;copy; 2005, Gold Bamboo LLC, All Rights Reserved</copyright>
      
	<item>
        <title>PREAMI: Perindopril and Remodelling in Elderly with Acute Myocardial Infarction</title>
        <link>http://goldbamboo.com/news-a148700.html</link>
        <description>The "high tissue" ACE inhibitor, perindopril significantly reduces the risk of death, hospitalisation for HF and cardiac remodeling in elderly post MI patients with preserved LV function according to results from the PREAMI (Perindopril Remodeling in Elderly with Acute Myocardial Infarction) study announced today at the European Society of Cardiology (ESC) annual meeting... click link for more info.</description>
		 <pubDate>Mon, 05 Sep 2005 11:00 EST</pubDate>
	</item>
	<item>
        <title>New Hope For Elderly Heart Attack Survivors</title>
        <link>http://goldbamboo.com/news-a150490.html</link>
        <description>PREAMI Study Shows Significant Benefit of Coversyl® in Elderly Post-Heart Attack Patients -   Results from the PREAMI (Perindopril Remodelling in Elderly with Acute Myocardial Infarction) study announced today at the European Society of Cardiology (ESC) Congress show that the ACE inhibitor Coversyl® (perindopril) significantly reduces the risk of death, hospitalisation for heart failure and cardiac remodelling in elderly post-heart attack patients with preserved left ventricular (LV) function... click link for more info.</description>
		 <pubDate>Fri, 09 Sep 2005 11:00 EST</pubDate>
	</item>
	<item>
        <title>Two New Treatment Advances For Coronary Artery Disease Patients</title>
        <link>http://goldbamboo.com/news-a150722.html</link>
        <description>EMEA gives go-ahead for Coversyl® (perindopril) indication in stable CAD and marketing authorisation for  Procoralan® (ivabradine), the first exclusive heart-rate reducing agent -  Servier announced at the European Society of Cardiology (ESC) two major advances that will potentially help millions of patients with coronary artery disease (CAD)... click link for more info.</description>
		 <pubDate>Sun, 11 Sep 2005 09:00 EST</pubDate>
	</item>
	

    </channel>
  </rss>
